DESIGN OF MEDICAL DEVICES CONFERENCE, CHINA 2018

DEC.10-12, 2018 BEIJING, CHINA

CONFERENCE PROGRAM

Hosts:
Earl E. Bakken Medical Devices Center, University of Minnesota
Neos Discovery Capital, LLC
Beijing Health Promotion Association
International Technology Transfer Network (ITTN)

Organizers:
Advanta Science Events (Beijing) Co., Ltd.
Zhongguancun Medical Device Park Co., Ltd.
MaTRineX Academy of Food and Drug Innovation Development

Guided by:
China Center For Food and Drug International Exchange

Supporter:
Beijing Pharma and Biotech Center (BPBC)

Co-organizers:
School of Medical Instrument and Food Engineering of University of
Shanghai for Secience and Technology
Sp@ce=Comp@ss
Beijing Zhongguancun XinxiQu Assets Management Co. Ltd.
Zhongguancun Advanced Medical Device Park, as an unique industrial park, is established by Zhongguancun Development Group together with the People’s Government of Daxing District, under the instruction of “strengthening the cooperation between the central government and local governments at all levels and the Cooperation between urban areas, actively integrating into the expansion development of demonstration zone and achieving win-win” by the Beijing Municipal Committee of Communist Party of China and the People’s Government of Beijing Municipality. It introduced China Communications construction Group as a strategical investor and is the first industrial park operated by Zhongguancun Development Group since the establishment of the latter. Located in the central area of Phase III of Daxing Bio-medicine Industrial Base, the park occupies a construction area of about 400,000 square meters, with a construction area around 190,000 square meters at Phase I and around 210,000 square meters at Phase II, Phase I was implemented in 2017.

Following the development idea of “high-end leader, innovation demonstration, industrial ecology and function optimization”, Zhongguancun Advanced Medical Device Park will give priority to high-end medical device industry, integrate into the function of R&D, industrial incubator, production and service and focus on developing the following four industrial functions: high-end medical device R&D headquarters, the manufacturing of new and high-end device, the incubation and growth of medical device enterprises as well as the supporting services of medical device. The development and operation of the Park will be “supported by governments, led by Zhongguancun Development Group, participated into by enterprises, attracted enterprises to enter into in cluster and be market-oriented”. Resources of medical device industry are highly expected to cluster into the park after it is completed.
CONFERENCE INTRODUCTION .................. 02
CONFERENCE ORGANIZATIONS ............ 03
CONFERENCE AGENDA ..................... 09
CONFERENCE SPEAKERS ................... 13
CONFERENCE SPONSORS .................. 34
Conference Advisory/Speaker Panel .... 36
CONFERENCE SERVICE .................... 38
CONFERENCE INTRODUCTION

Design of Medical Devices Conference (DMD) is launched by University of Minnesota in 2001, aimed to strengthen the cooperation between academic world and industry, facilitate medical device-related policies, research and education. Meanwhile, it also supports University of Minnesota in medical device education.

The conference is open to one of the world’s most advanced medical device communities, and continues to promote industry through extraordinary insight and leadership. Over the years, DMD has more than 15,000 attendees, more than 2,000 speakers, and more than 1000 abstracts/technical briefings published in ASME.

In 2017, DMD entered into China. Design of Medical Devices Conference, China 2017 (DMD China 2017) was held in Beijing in November 2017. It is planned to be an annual fixed event and invite experts and set up sessions in Chinese medical device development, device approval, and clinical needs and so on.

Design of Medical Devices Conference, China 2018 (DMD China 2018), the second conference with the theme of “international exchanges and technological innovation”, will be held on Dec. 10-12, 2018 in Beijing International Conference Center. DMD China 2018 will focus on policy interpretations, hot points, design training, advanced technology release, exhibition of medical device. Besides, it will attract world-class excellent designers, research scholars, approving authorities, manufacturers, healthcare organizations and public management departments in medical devices to attend this conference.
The Earl E. Bakken Medical Devices Center (Bakken MDC) at the University of Minnesota is an interdisciplinary program that sits within the Institute for Engineering in Medicine and combines basic research, applied and translational research, education and training, and outreach and public engagement all related to medical devices. The Bakken MDC brings together the University of Minnesota's expertise from the College of Science and Engineering and the Academic Health Center (School of Dentistry, College of Veterinary Medicine, School of Nursing, College of Pharmacy and the Medical School).

In July of 2017, the Medical Devices Center was renamed in honor of UMN Alumnus and Medtronic, Inc. Co-Founder, Earl E. Bakken. “The Medical Devices Center wouldn’t be possible without the foundation Earl Bakken built in Minnesota,” said Arthur Erdman, Ph.D., director of the Earl E. Bakken Medical Devices Center. “Having his name officially associated with our center is an honor, and we are committed to continuing to live up to his charge, to create new technologies to improve health.”

In April 2013, the Bakken MDC moved into its 8,000 square foot home located in the Mayo Building on the East Bank Campus. The Bakken MDC aims to strengthen interdisciplinary research among faculty in the health sciences and engineering specifically related to medical devices. The center will help train the next generation of medical device inventors and foster new relationships with the successful Twin Cities medical device industry and various government agencies in an effort to improve health care worldwide.

One of the crown jewels of the Bakken MDC is the Innovation Fellows Program, which began in 2008. The goal is to train the next leaders in medtech by fostering leadership and teaching risk management for medical devices. The Bakken MDC teaches the Innovation Fellows disciplined product development which includes FDA Requirements, Insurance Reimbursement, Intellectual Property and Business Strategies in addition to Creativity Techniques and Prototyping.

The Innovation Fellows spend their first few weeks in a series of Educational Rotations presented by thought leaders in the College of Science and Engineering, Medical School, Academic Health Center, law firms, surrounding med-tech industry, venture capitalists and angel investors. They then spend several weeks in a period of Clinical Immersion, where they put on scrubs and stand in the periphery of operating rooms and clinics and observe MD, nurses, and associated technicians at work.

After collecting unmet clinical needs, they will define the problem from all angles, using clinical literature as a guide. The Innovation Fellows work with UMN faculty collaborators from both engineering and medicine and interface with University technology transfer and licensing groups. They will innovate around unmet clinical needs for the duration of the fellowship. This includes multiple sets of prototyping cycles and bench top testing. In addition, the Innovation Fellows teach, share and learn by mentoring undergraduate and graduate student design teams from across the College of Science and Engineering, support the Design of Medical Devices Conference, and interact with the College of Design's Product Design Program.

The Bakken MDC provides a unique environment with extensive prototyping equipment, support staff and interface with the University of Minnesota Medical Center, Fairview. Our Bakken MDC Innovation Fellow sponsors are offered preferred access to both the new facilities and to new intellectual property.

The Innovation Fellows have been very successful, generating over 200 invention disclosures within the first eight years, 5 start-up companies, 88 patent applications, 26 product licenses from 48 current and alumni Fellows.
Neos Discovery Capital LLC

Founded by venture capital experts and relevant scientists, Neos Discovery Capital LLC is an enterprise integrating venture investment and technology trade. It aims to cultivate world-class enterprises and entrepreneurs by relying on advanced technology and capital in the United States and around the world. In order to meet rapid development of the capital and technology demand of China, Neos Discovery Capital LLC brings in capital and technology to China continuously. The fund of Neos Discovery Capital LLC comes from the endowment fund of first-class universities, family fund and enterprise incubation fund in the United States, China and Europe; The technology of Neos Discovery Capital LLC comes from national governments, world-renowned universities and research institutes of enterprises. Neos Discovery Capital LLC has broad channels and profound professional background in medical devices, biology and new material technology, its team has rich experience in investment, entrepreneurship and management, and it owns many industry resources in the related industries in the United States.

Beijing Health Promotion Association

Beijing Health Promotion Association (BJHPA) was established on May 8, 1998. It is a regional, public welfare, professional and non-profit social organization which is formed voluntarily by the workers of Beijing medical and health system and related units under the support of the competent government departments and related departments and registered under the approval of Beijing civil affairs bureau. It aims to use the administrative or organizational means such as Beijing medical treatment, health and education to extensively coordinate the relevant departments of the society as well as communities, families and individuals, so that they can fulfill their respective responsibilities for health and jointly maintain and promote the health of Beijing citizens.

International Technology Transfer Network (ITTN)

International Technology Transfer Network (www.ittn.com.cn) was established in 2011 with a secretariat in Beijing. Initiated and established by Beijing municipal commission of science and technology, ITTN is now under the guidance of China association for international scientific and technological cooperation and established the international technical transfer committee of China association for international scientific and technological cooperation in 2016. ITTN is a professional international organization dedicated to promoting international technology transfer and innovation cooperation. It carries out international innovation related work through uniting well-known professional technology transfer and innovation service institutions at home and abroad. ITTN has invited more than 140 international technology transfer organizations, university technology transfer offices and influential figures of innovation institutions to join ITTN international committee, and established cooperation with more than 400 international technology transfer agencies in more than 40 countries to establish a global resource collaboration network. Meanwhile, entrusted by the People’s Republic of China ministry of science and technology, Beijing science and technology commission, ITTN
takes on more than 20 specific work of official mechanism of international cooperation in science and technology innovation platform, such as China-Italy technology transfer center, China-Italy innovation and entrepreneurship competition, China-America university technology transfer collaboration network, China-South Korea enterprise cooperation innovation center, APEC member economies talent training program and so on. ITTN secretariat, international technology transfer professional committee, steering committee, professional collaboration system and sub-centers across 11 provinces and municipals have formed a mature and complete domestic support system. The international and domestic two-way connection and landing is carried out through the seven business sectors of innovation data, innovation exhibition, innovation training, innovation communication, innovation investment, innovation real estate and research.

Organizers:

Advanta Science Events Co. (Beijing), Ltd.

Advanta Science Events Co. (Beijing), Ltd. focuses on the international cooperation of medical devices, mainly including international conference and exhibition of international medical devices, introduction and consultation of international technology and products of medical devices, medical device design training, and international exchange and cooperation of medical devices. Currently, the company focuses on the domestic promotion and development of the Design of Medical Devices Conference (DMD) of Medical Device Design Center at the University of Minnesota; establishing domestic brand DMD China; assisting in promoting the medical device design training program of Medical Device Design Center at the University of Minnesota; further promoting the introduction and implementation of promising international medical device technology and projects.

Zhongguancun Medical Device Park Co., Ltd.

Zhongguancun Advanced Medical Device Park, as an unique industrial park, is established by Zhongguancun Development Group together with the People’s Government of Daxing District, under the instruction of “strengthening the cooperation between the central government and local governments at all levels and the Cooperation between urban areas, actively integrating into the expansion development of demonstration zone and achieving win-win” by the Beijing Municipal Committee of Communist Party of China and the People’s Government of Beijing Municipality. It introduced China Communications construction Group as a strategical investor and is the first industrial park operated by Zhongguancun Development Group since the establishment of the latter. Located in the central area of Phase III of Daxing Bio-medicine Industrial Base, the park occupies a construction area of about 400,000 square meters, with a construction area around 190,000 square meters at Phase I and around 210,000 square meters at Phase II, Phase I was implemented in 2017.

Following the development idea of “high-end leader, innovation demonstration, industrial ecology and function optimization”, Zhongguancun Advanced Medical Device Park will give priority to high-end medical device industry, integrate into the function of R&D, industrial incubator, production and service and focus on developing the following four industrial functions: high-end medical device R&D headquarters, the manufacturing of new and high-end device, the incubation and growth of medical device enterprises as well as the supporting services of medical device. The development and operation of the Park will be “supported by governments, led by Zhongguancun Development Group, participated into by enterprises, attracted enterprises to enter into in cluster and be market-oriented”. Resources of medical device industry are highly expected to cluster into the park after it is completed.
MaTRineX Academy of Food and Drug Innovation Development

MaTRineX Academy of Food and Drug Innovation Development is oriented to the frontier of international pharmaceutical science and technology and is cooperating with pharmaceutical research & development institutions, aiming to build a national pharmaceutical research platform. The research academy gives full play to the role of bridge, provides all-round guidance for the food and drug enterprises, strengthens the communication and exchange between research institutions and production enterprises in research and development, so as to improve the level of domestic food and drug research & development and solve the application problems encountered in actual production. Secondly, the academy studies the operational points of food and drug declaration and technical review, and the core problems encountered in the process of research declaration, so as to provide suggestions and opinions for the successful passing of the review. At the same time, the academy also promotes in-depth cooperation in food and drug science, research and production, and promotes the healthy development of the food and drug industry at home and abroad.

Guided by:

China Center For Food and Drug International Exchange

China Center for Food and Drug International Exchange is an independent legal entity directly under the State Food and Drug Administration. Main responsibilities and business scope: (1) Carry out international exchanges and cooperation related to food and drug according to the supervision work of food and drug, and organize exchanges and cooperation between the mainland and Hong Kong, Macao and Taiwan; (2) Organize and implement non-official food and drug international exchange and cooperation projects; (3) Be responsible for the unofficial official visits and receptions of food and drugs outside the state (border) of the state administration and directly affiliated institutions; To arrange visits and receptions by foreign non-governmental organizations and civil institutions; (4) Organize related overseas group and overseas training; (5) Hold international exhibitions and conferences on food and drug, and carry out relevant technical exchanges and consultation services; (6) Organize and conduct research on international policies and regulations of food and drug and undertake related information services; (7) Undertake the technical examination and verification of the registration and establishment of representative offices of overseas non-governmental organizations involved in the field of food and drug in China; (8) Undertake the preliminary examination of the work related to overseas (frontier) training, holding international meetings, and approval documents for overseas (frontier) missions of the general administration and directly affiliated institutions; (9) Be responsible for handling related work of passports (passports) and visas (endorsements) of personnel who go abroad on business of general administration and directly affiliated institutions, and be responsible for the daily management and safekeeping of official passports (traffic permits); (10) Undertake other tasks assigned by the State Food and Drug Administration.
Supporters:

Beijing Pharma and Biotech Center (BPBC)

Since founded in 1996, Beijing Pharma and Biotech Center (BPBC) has dedicated itself to the establishment and promotion of the new pharmaceutical and biotech industry in Beijing. Known for its forward thinking, BPBC has been leading the development of the biopharmaceutical industry in China. In addition, it has been a strategic consultant for domestic grown enterprises, local expert for multinational corporations, and advisor for policy makers in government.

Co-organizers:

School of Medical Instrument and Food Engineering of University of Shanghai for Science and Technology

College of Medical Devices and Food of Shanghai University of Technology was established in September 2006, which was established to integrate medical devices, food and refrigeration and cryogenic disciplines of Shanghai University of Technology in response to national strategic and industrial needs. The medical devices discipline has a history of more than 50 years, and it is the only medical device discipline in China independently established to train high-level medical device talents. Food science and engineering relies on the key disciplines of refrigeration and cryogenic engineering to build a food science with unique engineering features. The college has a strong team of professional teachers, including 58 professors and associate professors, 82 percent of whom have doctoral degrees, including more than 20 talents at various levels, such as National Million Talents, National Plan of 10,000 People, New Century Talents of the Ministry of Education, Leading Talents of Shanghai, Distinguished Professors of Oriental Scholars, Scholars of Pujiang, etc. Professor Weiqi Wang, academician of the Chinese Academy of Engineering and a renowned biomedical engineering expert, is the honorary President of the college, and Zezhao Hua, the first national master of teaching and a renowned expert in cryogenic biomedical technology, served as the chief professor of the college. The college mainly trains senior engineering and management applied talents in the fields of medical equipment, medical engineering equipment, food processing and food safety and quality control. "Medical device engineering" is listed as a key subject in Shanghai, and is the first "modern minimally invasive medical devices and technologies” engineering research center of the ministry of education approved by Shanghai local universities; "Medical equipment professional group” and "food quality and safety” were listed as education highland for undergraduate students in Shanghai. "Medical engineering and food safety" is one of the six major subjects in Shanghai University of Technology. The college relies on industry to serve society. The company has set up the training center for food safety engineers and the China office of "Shanghai University of Technology -- American Medical Regulations Association”. It provides a systematic opportunity for professionals engaged in the research, development, production, operation and supervision of medical devices and food, and promotes the integration of China’s medical devices regulations education with the international level.
Sp@ce•Comp@ss

Founded by Mr. Aiming Liu, former executive Vice President of Vanke, Space Holding Group focuses on industrial real estate development and operation and management of industrial parks, and gathers Vanke group, Zhongcheng investment, World Union and other strong listed companies as strategic investment shareholders. Space Holding Group adheres to the development concept of "Industry First, then Real Estate", aiming to practice industrial upgrading and serve the transformation and upgrading of Chinese manufacturing enterprises. The industrial innovation system service platform of Comp@ss focuses on planning, investment, construction and operation of industrial innovation system; focuses on medical devices, intelligent manufacturing, Beidou industry, internet of things industry and other vertical industries; dig deep into industrial chain resources and provide a complete series of services related to space operation, innovation and entrepreneurship services and industrial investment. Comp@ss will set up a number of innovation centers in major domestic cities such as Shenzhen, Beijing and Shanghai, as well as major countries around the world, integrate global industrial resources, provide whole-chain services, facilitate the internationalization of enterprises, and facilitate industrial transformation and upgrading.

Beijing Zhongguancun Xinxigu Assets Management Co. Ltd.

Beijing Zhongguancun Xinxigu Assets Management Co. Ltd (hereinafter referred to as XXG) was established and wholly owned by Zhongguancun Management Committee and Zhongguancun Development Group LLC on November 21st 2014. In respond to the Strategy of Innovation-driven Development, Beijing-Tianjin-Hebei Integration Development Strategy and Zhongguancun 1+6 Policy, Zhongguancun Development Group LLC set up Xinxigu Beijing as its subsidiary company.

As a light-asset enterprise, XXG mainly concentrates its profession on the service of science industry and the operation of hi-tech park. Based on the advantage of science and technology resources of Zhongguancun, Xinxigu devotes itself into the gathering more promising hi-tech enterprises to its innovation ecosystem.

With the guide and support from the municipal and provincial governments, XXG has set a series of innovation platforms——Innovation Center, Innovation Demonstration Base, Innovation Forum Union, Rainforest Co-Working Space and a various brand industrial activities. Through these innovation platforms, space, political support (e.g. favorable tax policy) as well as financial support (e.g. fund and investment), XXG has gathered a great number of outstanding hi-tech enterprises in its cooperated cities and has accelerated the economy progress. Meanwhile, these hi-tech enterprises further expand their market. Therefore, XXG is performing the virtuous circle and cooperative platform for the cities and the enterprises.
### Monday 2018/12/10  Beijing International Conference Center (BICC) Room No. 5AB

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-10:00</td>
<td>Registration/Check-in</td>
</tr>
<tr>
<td>10:00-10:15</td>
<td>Welcome &amp; Introduction</td>
</tr>
<tr>
<td>10:15-11:00</td>
<td>&quot;Needs Finding&quot; Joe Hale, Director, Earl E. Bakken Medical Devices Center Innovation Fellows Program, University of Minnesota</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>&quot;Clinical Needs Finding&quot; Gwen Fischer, Critical Care Physician, University of Minnesota Masonic Children's Hospital</td>
</tr>
<tr>
<td>11:30-12:15</td>
<td>Lunch Provided</td>
</tr>
<tr>
<td>12:15-13:00</td>
<td>Needs Finding Exercise</td>
</tr>
<tr>
<td>13:00-13:45</td>
<td>&quot;Brainstorming&quot; Joe Hale, Director, Earl E. Bakken Medical Devices Center Innovation Fellows Program, University of Minnesota</td>
</tr>
<tr>
<td>13:45-15:15</td>
<td>Prototyping Activity</td>
</tr>
<tr>
<td>15:15-15:30</td>
<td>Networking Break</td>
</tr>
<tr>
<td>15:30-16:15</td>
<td>&quot;Market Assessment&quot; Mike Finch, Children's Hospitals and Clinics, University of Minnesota Carlson School of Management</td>
</tr>
<tr>
<td>16:15-16:45</td>
<td>Report Out / Project Pitches</td>
</tr>
<tr>
<td>16:45-17:30</td>
<td>Q&amp;A w/ the Experts</td>
</tr>
<tr>
<td>17:30</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>

### Tuesday 2018/12/11  Beijing International Conference Center (BICC) Room No. 5

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:00</td>
<td>Registration</td>
</tr>
<tr>
<td>09:00-11:45</td>
<td>Welcome, Plenary and Keynote Presentations</td>
</tr>
<tr>
<td></td>
<td>Moderator: David Melander, VP Strategic Assessment, Neos Discovery Capital</td>
</tr>
<tr>
<td></td>
<td>Greetings:</td>
</tr>
<tr>
<td></td>
<td>Art Erdman, Director of the Earl E. Bakken Medical Devices Center, Founder and Chair of the Design of Medical Devices Conference</td>
</tr>
<tr>
<td></td>
<td>Joseph Wang, President, Neos Discovery Capital, Co-founder and Co-chair of the Design of Medical Devices Conference China</td>
</tr>
<tr>
<td></td>
<td>Yanfeng Gu, Division of American and Oceanian Affairs, Department of International Cooperation, Ministry of Science and Technology</td>
</tr>
<tr>
<td></td>
<td>Bin Xue, Deputy Director (Presiding), China International Food and Drug Exchange Center</td>
</tr>
<tr>
<td>09:00-11:45</td>
<td><strong>Keynote Presentation 1: &quot;The Future of Medical Devices in China&quot;</strong></td>
</tr>
<tr>
<td></td>
<td>Qiang Xu, Director, Beijing Municipal Science &amp; Technology Commission</td>
</tr>
<tr>
<td>09:00-11:45</td>
<td><strong>Keynote Presentation 2: &quot;Building a Collaborative Global Medical Device Community&quot;</strong></td>
</tr>
<tr>
<td></td>
<td>Randy Schiestl, VP, R&amp;D and Global Technology, Boston Scientific Corporation</td>
</tr>
<tr>
<td>09:00-11:45</td>
<td><strong>Keynote Presentation 3: &quot;Medical Devices for Global Markets&quot;</strong></td>
</tr>
<tr>
<td></td>
<td>Will Song, President, Johnson &amp; Johnson Medical China</td>
</tr>
<tr>
<td>09:00-11:45</td>
<td><strong>Keynote Presentation 4: &quot;Healthy China&quot;</strong></td>
</tr>
<tr>
<td></td>
<td>Rui Liu, World Bank Health, China</td>
</tr>
<tr>
<td>11:45-13:00</td>
<td>Lunch</td>
</tr>
<tr>
<td>Time</td>
<td>Session 1</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td><strong>Session 1</strong>&lt;br&gt;Topic: Innovation Through Collaboration&lt;br&gt;David Knapp, VP, R&amp;D, Boston Scientific Corporation</td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>Break</td>
</tr>
<tr>
<td>14:30-15:30</td>
<td><strong>Session 1</strong>&lt;br&gt;Topic: Computational Modeling and Simulations that Improve Patient Therapies&lt;br&gt;Marc Horner, Technical Lead, Healthcare, ANSYS, Inc.&lt;br&gt;Yu Feng, Assistant Professor, School of Chemical Engineering at Oklahoma State University&lt;br&gt;Andrew Fraser, Chief Resident, University of California Los Angeles School of Dentistry Section of Orthodontics</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Break</td>
</tr>
<tr>
<td>16:00-17:00</td>
<td><strong>Keynote Presentation:</strong> “Increasing International Cooperation in the Medical Device Industry”&lt;br&gt;Guorong Li, Chief Scientist, Researcher, State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital, Chinese Academy of Medical Sciences</td>
</tr>
</tbody>
</table>
### Wednesday 2018/12/12    Beijing International Conference Center (BICC) Room No. 5

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:00</td>
<td>Registration</td>
</tr>
</tbody>
</table>

**Keynote Presentations:**
Moderator: Joseph Wang, President, Neos Discovery Capital and co-chairman of Design of Medical Devices Conference (China)

**Keynote Presentation 1:** "Genetic Markers of Cardiac Disease"
Rutai Hui, Professor, Biochemistry & Genomic medicine, Peking Union Medical College & Chinese Academy of Medical Sciences

**Keynote Presentation 2:** "Major Recent Technology Advances in China Medical Device Technology"
Qinxian Jin, Dean, Office of Technology Transfer and Deputy Vice Secretary General, Tsinghua University

**Keynote Presentation 3:** "Science of Skin: The Challenges of Adhering Medical Devices to Skin"
Yann Ding, Sr. Application Development Engineer, 3M Medical Solutions Division China Laboratory

**Keynote Presentation 4:** "Current Situation of Medical Device Industry in China"
Wang Baoting, Director of Chinese drug supervision Seminar, Director of the Professional Committee on Medical Device Supervision and Research

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
<th>Session 2</th>
<th>Session 3</th>
<th>Session 4</th>
</tr>
</thead>
</table>
| 09:00-11:30| Topic: Glioblastoma Therapeutics  
Clark Chen, Lyle A. French  
Chair in Neurosurgery, Professor and Department Head of Neurosurgery, University of Minnesota Medical School  
Jiang Tao, MD, PhD, Professor. Director ad interim of Beijing Neurosurgical Institute Vice Chairman, Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University Chairman of Society for Neuro-Oncology of China, CMDA Founder of Chinese Glioma Genome Atlas (CGGA)  
Ma Xiao Dong, MD, PHD, Professor, Chinese PLA General Hospital, Beijing, vice chairman of Neurosurgery Department of Chinese PLA General Hospital, chiefsurgeon, professor, supervisor of doctoral degree student, finished a fellowship in Johns Hopkins University in the USA.  
Cong Li, MD, PhD, Professor, School of Pharmacy, Fudan University, Shanghai  
Dawn Bardot, Director, Healthcare Innovation, Medtronic, Inc.  
Gwen Fischer, Critical Care Physician, University of Minnesota Masonic Children's Hospital  
Nicholas Kucher, Medical Fellow, Pediatric Critical Care, University of Minnesota  
Kenneth Liao, Professor, Department of Surgery, University of Minnesota  
Yawei Xu Team from Heart Center of Shanghai TENTH People’s Hospital |

<table>
<thead>
<tr>
<th>Time</th>
<th>Lunch</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30-12:30</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Break</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-14:00</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session 1</td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>14:00-15:00</td>
<td><strong>Topic:</strong> China Capital Meets US Innovation - Investors’ Perspective</td>
</tr>
<tr>
<td></td>
<td>JC Sun, PhD, MBA, Claire W. Sha, Founder and Managing Partner, AriMed Group</td>
</tr>
<tr>
<td></td>
<td>Qiming (David) Sun, Co-founder and CEO, Maginitio Capital</td>
</tr>
<tr>
<td></td>
<td>George Li, Founder and Managing Partner, Proxima Ventures</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>Break</td>
</tr>
<tr>
<td>15:30-17:00</td>
<td><strong>Topic:</strong> Modern Medicine and Developing Countries</td>
</tr>
<tr>
<td></td>
<td>Sudesh Sivarasu, Associate Professor of Biomedical Engineering, University of Cape Town</td>
</tr>
<tr>
<td></td>
<td>Thiagarajan Keddin Alwar, Associate Professor, Sri Ramachandra Medical College</td>
</tr>
<tr>
<td></td>
<td>Dr. Emmanuel Dhiravia Sargunam, associate professor at the Sri Ramachandra Institute of Higher Education and Research (SRIHER), Chennai, India.</td>
</tr>
</tbody>
</table>
Art Erdman

Director, Medical Devices Center, University of Minnesota
Founder and Chair, Design of Medical Devices Conference, University of Minnesota

Arthur G. Erdman, PhD, is the Richard C. Jordan Professor and a Morse Alumni Distinguished Teaching Professor of Mechanical Engineering at the University of Minnesota, specializing in mechanical design, bioengineering and product design. In July 2007 he was selected as the Director of the Medical Devices Center at the U of M. He received his BS degree at Rutgers University, his MS and PhD at RPI. Dr. Erdman has published over 325 technical papers, 3 books, holds over 30 patents, and shares with his former students 9 Best Paper Awards at international conferences.

Dr. Erdman currently has a number of ongoing projects of which many are related to biomedical engineering and medical device design. He led the effort to create LINCAGES, a mechanism software design package that has been use worldwide. Dr. Erdman has had research collaborations with faculty in Ophthalmology, Neuroscience, Epidemiology, Orthopedics, Surgery, Dentistry, Otolaryngology and Sport Biomechanics. He has consulted at over 50 companies in mechanical and product design, including Xerox, 3M, Andersen Windows, Proctor and Gamble, HP, Rollerblade, Sulzer Medica and Yamaha. He has received a number of awards including ASME Machine Design Award and the ASME Outstanding Design Educator Award. Erdman is a Fellow of ASME and a Founding Fellow of AIMBE. He has been the Chair of fifteen Design of Medical Devices Conferences which are held on the University of Minnesota campus each April.

Joseph Wang

Chairman of Neos Discovery Capital LLC and co-chairman of Design of Medical Devices Conference (China)

Mr. Joseph Wang is an important thought-leader with significant economic impact at the intersection of business and technology. His work includes the creation of several international summits and conferences in highly leveraged fields of technology, including the latest advances in medical devices. He provides guidance and assistance in international corporate acquisitions and technology transfer. As Chairman of Neos Discovery Capital LLC, he has lead cooperation in technology between the US and China, funding technologies, enabling technology incubation, and commercialization in China.
Qiang Xu
Director of Beijing Municipal Science & Technology Commission

Yanfeng Gu
Division of American and Oceanian Affairs, Department of International Cooperation, Ministry of Science and Technology

Bin Xue
Deputy Director (Presiding), China International Food and Drug Exchange Center
Joe Hale

Director, Earl E. Bakken Medical Devices Center Innovation Fellows Program, University of Minnesota

Dr. Joseph Hale is an independent medical device consultant with expertise in new product and business development. His experience includes various roles - including biomechanical test design, US/OUS regulatory support and market analysis - with several start-up and early stage medical device companies, including Raymedica, Spineology and Conventus Orthopaedics. He is also an alumnus of the Earl E. Bakken Medical Devices Center Innovation Fellows Program at the University of Minnesota.

Joseph received a BS in Mechanical Engineering from Boston University, an MS in Bioengineering from Clemson University, and a PhD in Biomedical Engineering from the University of Iowa. In addition to the University of Minnesota fellowship in Medical Device Innovation, Joseph completed a post-doctoral fellowship in rehabilitation engineering/wheelchair mobility at the University of Virginia, where he discovered his passion for innovation as well as teaching and mentoring students. In the years since, he has taught in undergraduate and graduate engineering programs and orthopaedic surgery residency training programs at the University of Virginia and the University of Minnesota, as well as in the University of Minnesota program in physical therapy. He currently directs the three-semester practicum for the University of Minnesota Technology Leadership Institute’s master’s degree program in Medical Device Innovation.

Joseph is a co-inventor on four issued patents, with additional applications pending. He has authored 12 peer-reviewed publications, as well as several book chapters, and is a member of the American Society of Mechanical Engineers, American Society of Biomechanics, and the Orthopaedic Research Society. Joseph is also actively involved in his community as a member of the National Ski Patrol, a Captain/EMT with the Maplewood Fire Department and a volunteer adult leader for the Boy Scouts of America.

Joseph was a member of the Inaugural Class of the Innovation Fellows Program of 2008-2009.

Gwen Fischer

Critical Care Physician, University of Minnesota Masonic Children’s Hospital

Gwenyth Fischer is a pediatric Critical Care Physician at the University of Minnesota Masonic Children’s Hospital Pediatric Intensive Care Unit and Cardiovascular Intensive Care Unit. She is also an alumnus of the Medical Device Innovation Fellows Program at the University of Minnesota. Dr. Fischer founded and currently directs the Pediatric Device Innovation Consortium (PDIC), and is always focused on getting pediatric technologies to market. She has been a co-inventor of several adult and pediatric medical devices and currently acts as the clinical advisor for the Medical Device Center fellows program.

Mike Finch

Former Director, Medical Industry Leadership Institute, Executive-in-Residence, Professor, Carlson School of Management, University of Minnesota, Children’s Hospital Research, Executive

Michael Finch, Ph.D., received his degree in Sociology from the University of Minnesota. From 1984 through 1998 he was a member of the faculty of the Division of Health Services Research and Policy at the University of Minnesota where he reached the rank of Associate Professor with tenure. From 1998 through 2004 Dr. Finch was Director of Research Programs for UnitedHealth Group. He is currently a member of the Graduate Faculty at the University of Minnesota with appointments in the Carlson School of Management and the School of Public Health.

He teaches the required Healthcare Marketplace course for MILI and is one of the instructors for the Medical Industry Valuation Laboratory.
David Melander
VP Strategic Assessment

David Melander is a high level strategist in business launches across international borders. As a consultant he’s established manufacturing for US companies in China, using proprietary systems for costing, quality, licensing, and production maturity. (He holds over 150 entry stamps into China). He’s helped companies launch products, arrange distribution or other market-entry methods in several countries.

He is the co-author with Joseph Wang of several books published in China, including the American Export Register.

As a consultant on international procurement and marketing, he assisted US firms in contracting manufacturing assets in the People’s Republic of China opening up market access in the country and significantly reducing manufacturing cost. In doing this he developed proprietary systems for analyzing cost which continue to be used by his clients, resulting in significant competitive advantage.

Recently his strategic direction for a new bio-plastics company gained the company access to 8 new market countries. The marketing and social-benefit programs designed and executed for the company won the company the prestigious World Economic Forum and Schwab Foundation Social Entrepreneur of the Year (2013).

Mr. Melander is currently focusing on investing in and licensing new technologies (medical, new-energy/green-energy, agricultural, and transportation) to China’s major corporations in cooperation with China’s largest investment groups. He is Senior Vice President of Neos Discovery Capital LLC.

He assisted in establishment of a Joint Venture to enter the “closed” publication field in the People’s Republic of China. The project received highest level endorsements from both countries’ trade officials. Project garnered China national media attention with 3 national TV spots and in 7 major daily papers. He helped establish a Joint Venture to produce vaccines in India. David Melander has provided the highest-level consulting to the government of Indonesia on various Anti-Corruption and Public Relations/Public Affairs issues.

David Melander assisted Governor Perpich in development projects in Eastern Europe.

Guorong Li
Biomedical engineering researcher, professor

Guorong Li is not only a medicine doctor and postdoctoral fellow, but also a biomedical engineering researcher, professor, master tutor, associate chief physician. Now he is working in Fuwai cardiovascular disease hospital, Chinese Academy of Medical Sciences,majoring in cardiovascular disease. He mainly has deep research and exploration on the mechanism and treatment of heart failure, and has original views on the treatment of advanced heart failure and mechanical auxiliary circulation. He has undertaken 3 projects of national natural science fund and 2 projects of 863 project. In recent years, he has made important achievements in the field of artificial heart research. Since being engaged in postdoctoral research in Fuwai cardiovascular disease hospital, Chinese Academy of Medical Sciences in 1996, he has been engaged in artificial heart research for a long time under the guidance of academician Xiaodong Zhu, a famous cardiac surgery expert in China. He has developed many cardiac assist devices, such as “FWI” “FWII”implantable axial bleeding pump, “apical axis flow pump”, “axial pump full artificial heart”, “magnetic fluid suspension centrifugal pump”, “magnetic suspended centrifugal pump”. Among them, the implantable axial bleeding pump has been successfully carried out in animal experiments, and is now in the clinical trial stage, which is in the leading position at home. His “apical axis flow pump”, “axial pump full artificial heart” and “functional full artificial heart” are of high academic value and innovation, which have had a great impact on the field of cardiac surgery at home and abroad.

1977-1981: learn in Department of Medicine, Changzhi Medical College
1985-1989: Surgical Director of Shanxi Changzhi Commercial Staff Hospital
1989-1992: Master's degree, Shanxi Medical University
1992-1995: Study for a doctoral degree in Shanghai Second Medical University
1996-1998: Postdoctoral research in Fuwai Cardiovascular Disease Hospital,
Will Song
President, Johnson & Johnson Medical China

David Knapp
VP, R&D, Boston Scientific Corporation

David Knapp is a leader in Medical Device Development and Exploratory Research working to treat unmet clinical needs for 20 years. Dave’s current focus as Vice President of Corporate Research at Boston Scientific is on developing new solutions and fostering growth in White Space areas of the company and developing novel technical platforms that cut across all Boston Scientific Divisions. He is passionate about coordinating open collaborative efforts including developing relationships with external institutions and connecting functions to drive meaningful innovation. Dave also serves as a Board Member on the Boston Scientific Foundation, is the Executive Sponsor in Minnesota for the Employee Resource Group Leadership, Education and Allies for Disabilities, and is a member of the Boston Scientific Health Advisory Panel.

He holds a B.S. in Chemical Engineering from University of Michigan and a Ph.D. in Chemical Engineering from University of Minnesota where he is a Fellow of the Institute for Engineering in Medicine and a member of the External Advisory Board for the Department of Chemical Engineering and Materials Science. Dave also serves as a member of the External Advisory Board for the Center for Bioengineering Innovation and Design at Johns Hopkins University.

Dawn Bardot
VP of Technology Innovation, Medical Device Innovation Consortium (MDIC)

With more than 15 years of experience in medical devices, Dawn Bardot, PhD, brings a wealth of experience to her role as Vice President of Technology Innovation at the Medical Device Innovation Consortium (MDIC). She is passionate about the application of data analytics and modeling to improve health care and lower the cost of bringing products to market.

Over the course of her career, Dawn has worked with startup companies, government organizations and academia on data driven design and decision making, including high intensity focused ultrasound, patient specific noninvasive FFR and medical oxygen regeneration for space flight.
Tina Morrison
Ph.D. Deputy Director, Division of Applied Mechanics, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, U.S. Food and Drug Administration

Tina M. Morrison, Ph.D. Center for Devices and Radiological Health, Food and Drug Administration Tina Morrison is the chair of the new FDA-wide working group on Modeling and Simulation, sponsored by the Office of the Chief Scientist, which launched in 2017. She has been serving as the Regulatory Advisor of Computational Modeling for the Center for Devices and Radiological Health (CDRH) since 2012. In that capacity, she leads the Regulatory Review of Computational Modeling working group, which has developed guidance documents on the use of modeling and simulation in the regulatory evaluation of medical devices [1]. She dedicates much of her energy towards advancing regulatory science through modeling and simulation because she believes the future of medical device design and evaluation, and thus enhanced patient care, lies with computation and enhanced visualization [2]. She serves as Chair of the ASME V&V Standards Committee on Verification and Validation of Computational Modeling, the Subcommittee V&V40 on Computational Modeling of Medical Devices, where she is leading the development of a strategy to assess the credibility of computational models[3]. She is also working with a team at CDRH to implement this strategy into the review of premarket submissions that leverage computational modeling [4]. For seven years, she was a scientific reviewer on a variety of medical device premarket submissions in Cardiovascular Devices. She is the Deputy Director of the Division of Applied Mechanics in FDA’s Office of Science and Engineering Laboratories. She is a mechanical engineer who received her PhD in Theoretical and Applied Mechanics from Cornell University in 2006.

Yongheng Chang
China Center for Food and Drug International Exchange, China Food and Drug Administration, Deputy Director

Chang Yongheng served in the medical device factory for 7 years and served in pharmaceutical factory for 4 years. Since 1987, he has served in the state organs. He served as: Deputy Director of Department of International Cooperation of State Pharmaceutical Administration, Director of Foreign Product Registration Office of Medical Device Administrative Supervision Department of State Pharmaceutical Administration, Director of Product Registration Office of Medical Device Department of China Food and Drug Administration and Deputy Inspector of Medical Device Department of China Food and Drug Administration.

His current social positions are: Director of Beijing Society of Biomedical Engineering, Vice Chairman of Osteoporosis Committee of China Gerontological Society and Senior Member of Chinese Pharmaceutical Association.
Kenneth Liao

Professor, Department of Surgery
Surgical Director, Heart Transplantation Program, Head, Robotic & Minimally Invasive Cardiac Surgery Program, CMIS, Surgical Director, Transcatheter Valve Program
MD: Hubei Medical College, China
Residency: The 3rd University Hospital of Beijing University, Beijing, China (General Surgery); Brookdale University Hospital Medical Center, Brooklyn, New York. (General Surgery); University of Minnesota (Cardiovascular and Thoracic Surgery)
Fellowship: Albert Einstein College of Medicine Research Lab).
Doctoral Degree of Surgery (PhD Equivalent): Beijing University Medical School, Beijing, China.
Research Fellow (Dr. Robert Frater): Albert Einstein College of Medicine, Bronx, New York. (Cardiovascular Research Lab)
Intern: Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York. (General Surgery)

Marc Horner

Technical Lead, Healthcare, ANSYS, Inc.
Dr. Marc Horner is the lead healthcare specialist at ANSYS Inc. Marc joined ANSYS after earning his PhD in Chemical Engineering from Northwestern University in 2001. Marc began by providing support and professional services for biomedical clients, primarily in the areas of cardiovascular devices, drug delivery, packaging, microfluidics and orthopedics. During this time, Marc developed numerous modeling approaches that can be used to establish the efficacy and safety of medical devices. Marc now helps coordinate business and technology development for the health care sector in North America.

Yu Feng

Assistant Professor, School of Chemical Engineering at Oklahoma State University
In addition to being an Assistant Professor in the School of Chemical Engineering at Oklahoma State University, Dr. Feng is a center investigator in the Oklahoma Center for Respiratory and Infectious Diseases (OCRID). Yu Feng was a Research Assistant Professor and Lab Manager of the Computational Multi-Physics Laboratory (CM-PL) at North Carolina State University. He has also held an affiliation with the DoD Biotechnology HPC Software Applications Institute (BHSAI) as a Research Scientist II. READ MORE
Andrew Fraser
Chief Resident, University of California Los Angeles School of Dentistry Section of Orthodontics

Dr. Andrew Fraser is the chief resident at the University of California Los Angeles School of Dentistry Section of Orthodontics. In addition, Dr. Fraser is the lab manager for Professor Won Moon’s research lab, focused on clinical investigation into the effects of Dr. Moon’s patented non-surgical expander, the MSE. Dr. Fraser’s research is focused on the effects of maxillary skeletal expansion on the adult orthodontic patient’s breathing and airway. Dr. Fraser earned his D.M.D. degree from the University of Pennsylvania School of Dental Medicine in 2016. Dr. Fraser has an M.S. in biomedical engineering from Tufts University and was the recipient of a research fellowship in immunology and microfluidics at Harvard University in 2010.

Jing Xie
Vice President, Clinical Affairs & Office of Medical Affairs, Medtronic, Inc.

Dr. Xie currently serves as the Vice President, Clinical Affairs and Office of Medical Affairs at Medtronic Spine and Biologics. In this role, she strategically leads and directs clinical and medical affairs activities globally.

Prior to Medtronic, Dr. Xie was the Vice President of Clinical Affairs for the Medical Device Innovation Consortium (MDIC) where she worked closely with FDA, payers and industry on identifying challenges and opportunities to advance regulatory science with the mission to expedite patient access to innovative medical device technologies. Prior to that role, Dr. Xie was the Vice President of Global Clinical Affairs for Zimmer Biomet.

Dr. Xie holds a Bachelor of Science degree in analytical chemistry from Xiamen University as well as a Master of Science degree in chemistry and PhD in materials science from the University of Alabama. She also holds a Master of Science degree in computer science from Purdue University.

Brian Kersten
Divisional VP, International Regulatory Affairs, ABBOTT

Dr. Kersten is the Divisional Vice President, International Regulatory Affairs for Abbott. He has over 30 years experience working in the Biotechnology, Pharmaceutical and Medical Device industries. He has extensive regulatory experience in various stages of product development.

He is responsible for International Regulatory Affairs for Abbott’s medical device business units and related activities including establishing policy and strategy for the business units, overseeing the process of preparing all international product submissions; managing regulatory submission process through approvals; and ensuring compliance with all international regulatory and quality requirements as applicable.

Prior to joining Abbott, Dr. Kersten held several senior leadership positions within the healthcare industry, most recently as Vice President, Regulatory Affairs and Quality Assurance/Analytical Sciences at Nuvelo, Inc.

Dr. Kersten holds a bachelor’s degree in Chemistry from the University of Michigan, Dearborn, Michigan and a doctorate degree in Chemistry from Wayne State University in Detroit, Michigan.
Lucas Rice

Cyber Risk Services, Deloitte & Touche LLP

- Process solutions leader and PMO lead for Deloitte’s Product Safety and Security practice with the experience helping clients protect their connected products through the design, development and implementation of a structured product security program.
- Designed and developed Deloitte’s Product Security Maturity Model (PSMM) used it to assess the level of maturity of Product Security organizations and programs at a variety of clients from medical device manufacturers and healthcare providers to industrial manufacturer and technology organizations.
- Designed, developed, and implemented product security programs and solutions (e.g., program frameworks, governance models, policies, program strategies and roadmaps, security risk assessment processes, integration of security components into product or acquisition lifecycles, etc..) for global organizations in alignment with industry leading practices and guidance on product and information security, as well as both regulatory and customer requirements.
- Assessed and designed global product manufacturers’ privacy programs, including readiness plans for the roll-out of the European Union’s General Data Protecion Regulation (GDPR).
- Design and developed a Net Value at Risk (NVaR) framework for a global medical device manufacturer that states product security risk in terms of monetary value, helping executives make quantifiable remediation decisions.
- Performed threat modeling and an attack-kill chain analysis for a global medical device manufacturer by mapping cyber threats and vulnerabilities for specific products and determining potential primary or mitigating controls to remediate those threats and vulnerabilities.
- Bachelors of Science degree in Mechanical Engineering from Rensselaer Polytechnic Institute
- Masters of Science degree in Technology Commercialization and Entrepreneurship from Rensselaer Polytechnic Institute.

Baoting Wang

Counsel of the Department of Medical Devices Supervision of China Food and Drug Administration (CFDA)

He was Dean of the Central Hospital of Mining Bureau, Feicheng, Shandong, Deputy Director General of Health Department of Shandong Province, National Food Safety Ombudsman of SFDA, Director-General of the Department of Medical Device Supervision of SFDA, Chairman of Asian Harmonization Working Party successively before the current position.
Rutai Hui
MD PhD

Education:
1972-1982: Shandong University & Peking Union Medical College,
1987-1992: PhD in Clinical Science, University of Montreal, Canada,
1993-1996: Post doctor training, US NIH, NIEHS, Research Triangle Park, NC, USA

Professional Carrier:
1997-now: Professor, Internal Medicine; Professor, Biochemistry & Genomic medicine, Peking Union Medical College & Chinese Academy of Medical Sciences
1999-2008: Scientific Director, Chinese Academy of Medical Sciences, Cardiovascular Institute & Beijing FuWai Hospital
1998-now: Editor in Chief, J. China Molecular Cardiology
2007-2014: Director, Key lab. for Cardiovascular Genetics and Genomics, Ministry of Education, China
1998-2014: Director, Sino-German Lab. for Molecular Medicine, Ministry of Science and Technology, China
2001-2011: Chief Physician, Hypertension Center, Beijing Fuwai Hospital.
2011-2014: Associate Director, National Key lab. for Cardiovascular Diseases
2017-now: Chief Medical Officer, Bestnovo Co. (Genetics and Genomics) Beijing, China
2017-2018: Chief Medical Officer, InnoHealth, ZhongGuanCun Development Group, Beijing, China


Qinxian JIN
Dean of the Office of Technology Transfer and Deputy SecretaryGeneral , Tsinghua University

He leads the University's effort in connecting the research-driven academia with market-driven industry to create technology innovations. Under his leadership, the Office of Technology Transfer works on establishing an effective technology transfer system with multiple service modules to promote collaborations between Tsinghua's departments/schools and various industry sectors. The Office also manages the University's strategic investment platforms and international collaborative projects in technology transfer as well as several industrial research institutes that receive funding and support from the local governments and industries.

Yann Ding
Sr. Application Development Engineer, 3M Medical Solutions Division China Laboratory

Dr. Ding joined the 3M Health Care Lab in the China R&D Center as a technical supporting engineer and application development engineer in 2011.
Randy Schiestl
Vice President, R&D, Global Technology at Boston Scientific

Randall (Randy) Schiestl, PMP, is the Vice President, R&D, Global Technology at Boston Scientific, where he leads a team to deliver computational analysis, technology roadmapping, product design, packaging & labeling, knowledge management, engineering systems, product security and lab services. Randy’s current focus is on building Global Technical Community across the corporation, R&D Globalization and innovation best practices.

He has BSME, MBA and Executive MBA degrees from the University of Minnesota. Randy received the UMAA Alumni Service Award from the College of Science & Engineering and the Design of Medical Device Conference Award. He serves on multiple industry advisory committees and is a founding board member of the Medical Device Innovation Consortium.

Clark Chen
Lyle A. French Chair in Neurosurgery, Professor and Department Head of Neurosurgery, University of Minnesota Medical School

Clark C. Chen is an internationally recognized neurosurgeon, radiosurgery expert, and a brain tumor researcher. His research interest is focused on understanding the neuroscience of brain tumor physiology and advancement of technology development for brain cancer treatment. He received his B.S. in biology from Stanford University, M.S. in epidemiology from Columbia University, and M.D., Ph.D. from Harvard Medical School. As a Ph.D. candidate, Dr. Chen studied under Dr. Richard Kolodner, a Nominee for the 2015 Nobel Prize in Chemistry, and discovered the genetic basis of familial cancer predisposition syndromes. He subsequently completed his neurosurgery training at the Massachusetts General Hospital, Harvard Medical School. His clinical neurosurgical training included dedicated fellowships in radiosurgery and stereotactic neurosurgery.

He currently serves as the Lyle French Chair in Neurosurgery and the Head of the University of Minnesota Medical School Department of Neurosurgery. Prior to this role, Dr. Chen served as the Vice-Chairman of Neurosurgery at the University of California San Diego and the Director of Surgical Neuro-oncology at the Beth Israel Deaconess Medical Center, Harvard Medical School. Dr. Chen is an NIH funded investigator and the recipient of highly regarded awards including: the Damon Runyon Fellowship Award, the Burroughs Wellcome Foundation Career Award in Medical Sciences, the Sontag Foundation Distinguished Scientist Award, the Doris Duke Foundation Clinical Scientist Award, and the Forbeck Scholar award. In 2015, Dr. Chen received the Presidential Award of Achievement from the President of Taiwan, Ma Ying-jeou. The award is conferred by the Taiwanese government to individuals of Taiwanese heritage who have made exceptional contributions to their profession.
Tao Jiang
Director ad interim of Beijing Neurosurgical Institute, Vice Chairman, Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Chairman of Society for Neuro-Oncology of China, CMDA, Founder of Chinese Glioma Genome Atlas (CGGA)

Dr. Tao Jiang is the Director ad interim of Beijing Neurosurgical Institute and vice Chairman of Department of Neurosurgery, Beijing Tiantan Hospital, which is one of the world’s largest neurosurgical centers. He has more than 20 years’ working experience on both clinical practice and scientific research of neurosurgery, and he performs more than 500 cases of neurosurgical operations per year.

Dr. Jiang founded the Chinese Glioma Tissue Database (CGTD) in 2004, followed by Chinese Glioma Genome Atlas (CGGA) in 2008, and co-founded the Asian Glioma Genome Atlas. His researches are mainly on “awake craniotomy”, “Glioma associated seizure” and “molecular classification and personalized medicine of glioma”. He has published more than 100 articles and won more than ten national and provincial awards.

Dr. Jiang is the founder, former director (2012-2014) and a member of the Chinese Glioma Cooperative Group (CGCG), which unites the main neurosurgical centers around China to provide more opportunities for deep collaboration. CGCG has been helping greatly in publishing clinical guidelines, organizing training classes, seeking for cooperation, and improve the standards of China’s neurosurgery.

Dr. Jiang serves as Chairman of GBM AGILE Executive Committee China Liaison, (A new generation clinical trial for GBM will be adaptive based on learning from the patients globally); Chairman of Society for Neuro-oncology of China, Chinese Medical Doctor Association; Vice Dean of Department of Clinical Oncology, Capital Medical University; the Regional Editor of Current Signal Transduction Therapy in Asia and Academic Editor of PLOS ONE.

Xiao Dong Ma
MD, PhD, Professor, Chinese PLA General Hospital, Beijing

Xiaodong Ma, vice chairman of Neurosurgery Department of Chinese PLA General Hospital, chiefsurgeon, professor, supervisor of doctoral degree student, finished a fellowship in Johns Hopkins University in the USA.

Cong Li
MD, PhD, Professor, School of Pharmacy, Fudan University, Shanghai

Dr. Cong Li obtained his Ph.D. degree from University of Hong Kong in 2004. After four years of postdoctoral fellow training in Department of Radiology, School of Medicine of Johns Hopkins University, he started his own lab in 2009 in the School of Pharmacy, Fudan University. Dr. Li has published 50 papers as corresponding or first author in prestigious journals such as Adv Mater, Angew Chem Int Ed, Nano Lett, ACS Nano, Chem Sci, J Cereb Blood Flow & Metab and holds three authorized patents. Dr. Li's research focuses on research frontier of “Molecular Imaging & Imaging Probes” and the applications of molecular probes in diagnosis and treatment of malignant brain tumor and other central nervous system (CNS) diseases. Achievement on “brain tumor imaging and drug delivery” was awarded the 2nd Prize of 2015 National Science and Technology Advance Award (2nd award winner).
Nicholas Kucher
Medical Fellow, Pediatric Critical Care, University of Minnesota

Nicholas Kucher is a second-year pediatric critical care fellow at the University of Minnesota Masonic Children's Hospital. Current areas of interest include medical education, medical simulation, and technology-patient integration.

Liang Tao
President of Wuhan Asian Heart Hospital and Director of Cardiac Surgery

Liang Tao graduated from the medical department of Peking University in 1986 with a bachelor’s degree in clinical medicine. He participated in cardiac surgery training of Singapore Central Hospital from March 1994 to March 1997. Currently, he is President of Wuhan Asian Heart Hospital and director of cardiac surgery. Professor, School of Medicine, Wuhan University of Science and Technology; master’s degree tutor, Wuhan University; adjunct professor, the first affiliated hospital of Medical College of Shantou University.

Member of the international society of minimally invasive cardiac surgery; vice chairman of the academic committee of the Chinese branch of AAHVD; chairman of professional committee of cardiovascular surgery, China Association of Non-public Medical Institutions; standing member of the fourth committee of cardiovascular surgeons branch, Chinese Medical Doctors Association; member of cardiothoracic surgery group, 8th committee of pediatric surgery branch, Chinese Medical Association; member of the ninth committee of thoracic cardiovascular surgery branch of Hubei Medical Association; chairman of the professional committee of cardiovascular surgery technology and engineering, Chinese Association of Pharmaceutical Biotechnology; vice chairman of the sixth committee of thoracic cardiovascular surgery branch of Hubei Medical Association; chairman of the professional committee of cardiovascular surgery, Chinese Association of Non-public Medical Institutions; vice chairman of the special committee of cardiac valvular disease of Chinese Research Hospital Society; editorial committee member of the fourth editorial committee of the journal—Clinical Pediatric Surgery.
Yawei Xu

Doctor of Medicine, Professor, Chief Physician, Doctoral Supervisor, Model Worker of Shanghai, the First Top Ten Benevolent Doctors of Shanghai, the Second National Famous Doctor. Currently, He is the Director of the Heart Center of Shanghai 10th People’s Hospital.

Chief scientist of national key research and development program
Vice chairman of internal medicine branch of Chinese Medical Association
President of cardiovascular physicians branch of Shanghai Medical Doctor Association
Member of electro cardiology and pacing branch of Chinese Medical Association
Member of the standing committee of the branch of cardiovascular physicians, Chinese Medical Doctor Association
Executive deputy leader of cardiac rehabilitation group, branch of cardiology, Chinese Medical Association
Vice President of the School of Atrial Fibrillation, China Atrial Fibrillation Center
Executive chairman of Shanghai Chest Pain Center Alliance
Secretary-general of the World Association of Chinese Cardiologists (WACC)
Vice chairman of left atrial occlusion working committee of electocardiology and pacing branch of Chinese Medical Association
Director of cross-strait medical and health exchange association and executive vice chairman of cardiovascular committee
Vice chairman of the thrombosis expert committee of the branch of cardiovascular physicians, Chinese Medical Doctor Association
Vice chairman, cardiac rhythm and electro cardiology branch, China International Exchange and Promotive Association for Medical and Health Care
Vice chairman of cardiovascular interventional medicine committee of Chinese Research Hospital Association
Member of the standing committee of chest pain specialty committee of Chinese Medical Doctor Association
Member of the professional committee of internal medicine for standardized training of resident physicians of Chinese Medical Doctor Association
Member of the expert committee of standardized training for cardiologists of Chinese Medical Doctors Association

He has been engaged in clinical and scientific research of cardiovascular diseases with comprehensive skills for many years. He is skilled in many interventional therapies, such as coronary heart disease catheter interventional therapy, arrhythmia radiofrequency ablation, permanent pacemaker installation, congenital heart disease interventional therapy, mitral valve balloon angioplasty, atherosclerotic peripheral vascular disease interventional therapy, laser erosion, coronary artery endometriosis, etc.

Specializes in the overall treatment of coronary heart disease through the radial artery path. Committed to the treatment of acute myocardial infarction for more than 20 years.

JC Sun
PhD, MBA

Mr. Sun has extensive experiences in the global MedTech industry, including R&D, strategic consulting, sales, venture capital, cross border acquisition & integration, and global marketing. Born and raised in China, Mr. Sun received his engineering PhD and MBA in USA. He has worked and lived in USA, Europe, and China, and has been actively working with and learning from clinicians and KOLs around the world. Mr. Sun is experienced in the process of turning innovative ideas into successful commercialization and equity transactions. He is the inventor of more than 10 issued patents within the MedTech field, including 8 US patents, and has led new product launch in USA, Europe, and Asia. He also served on the core team to lead and manage Medtronic Invatec $500M acquisition and integration (based in Switzerland from 2010 to 2012). Mr. Sun is also known to be an active “Partner of Entrepreneurs”, especially on cross border equity financing and strategic partnership, helping entrepreneurs gain access to the greater China capital market and commercial market.
Claire W. Sha

Founder and Managing Partner, AriMed Group

Claire W. Sha, MD is the Founder and Managing Partner of AriMed Group since 2011. Claire has over 20 years of experience in the Life Sciences & MEDTECH industry in China and North America as a venture capitalist, senior management executive, entrepreneur, and Physician. As a venture capital investor, her past affiliations include Panlin Capital (Venture Partner) and DFJDragon Fund (EIR).

Representative Investments include KangNing Psychiatric Hospital Group (02120.HK, IPO 11/20/2015), Hybribio (300639, Shenzhen A, IPO 04/12/2017), Viewhigh Technology (acquired by Nerosoft 2014), BioNano Genomics (BNGO.US, IPO 08/22/2018). She also invested in Applied StemCell Ltd. (ASC), US Milpitas based, a world leading gene editing company; Heartech Ltd, treating Heart failure; Ligatech, a medtech startup in Sport Medicine; DIH Technology Ltd., a leading digital robotic rehab and pharmacy management technology solution company and xCures, an AI based technology & platform to run virtual trials within AriMed portfolio.

As a financial advisor, Claire helps companies from its incubation, till expansion growth like early/seed stage Ustar biotech (POCT diagnostic), Cardramedsystem (Woman’s health), and Suzhou SceneRay (CNS), and growth expansion like KangNing Psychiatric Hospital Group, Hybribio Ltd, BenQ Hospital Group, and a buy-out deal leaded by Blackstone group acquired a domestic orthopedics company - XR Best medical instrument Ltd.

Qiming (David) Sun

Co-founder and CEO, Maginitio Capital

Qiming (David) Sun, PhD, MD is an orthopedist-turned investor, with over 25 years' experience in the healthcare sector. David is the co-founder and CEO of Maginitio Capital, focusing on the investments within medical devices & biomedical engineering field. His successful portfolio investments include Venus Medical, Boya Bio-pharmaceutical, Shanshi Medtec, etc. David is particularly interested in innovative medical devices and strives to accelerate their commercialization in China.

George Li

Founder and Managing Partner, Proxima Ventures

Mr. Li has over 12 years' global experience of investment, start-up, and business consulting in the MedTech industry. He is a member of innovation advisory committee for State Oversea Chinese Affairs office, the chair judge of “Chun Hui” business plan competition, and an entrepreneurship mentor for Zhejiang University. Mr. Li has incubated over 30 medical start-up companies including the first drug coated stent in China, 3D cell culturing technology, HPV diagnostic kits for China market. Mr. Li is the founder and managing partner of Proxima Ventures, which is a venture capital fund dedicated to growth stage innovative medical technologies to address unmet clinical needs in China. His portfolio companies include LungCare, Med-Pace, Cygnusbio, Tangee, Arigin Medical, etc. Mr. Li is also the founder and CEO of Biohub, which is a leading life science incubator/accelerator in China and has facilities in first-tier life science clusters in Wuhan, Hangzhou, Zhengzhou, Chengdu, and Chongqing.
Douglas Portnow
Principal, Schwegman Lundberg & Woessner

Doug Portnow is a registered patent attorney and a Principal of Schwegman Lundberg & Woessner. His practice focuses on patent preparation and prosecution, IP due diligence and strategic counseling in the medical device and mechanical technologies. Prior to joining Schwegman, Doug was a Member at Wilson Sonsini Goodrich & Rosati and an associate at Townsend and Townsend and Crew LLP (now Kilpatrick Townsend & Stockton). Before entering the legal profession, Doug worked for over a decade in the medical device industry holding engineering and management positions at start-ups and publicly traded companies commercializing critical care products, vascular grafts, surgical instruments, stents, stent delivery systems, RF ablation catheters, embolic protection devices, and heart failure implants. Doug has been recognized as a Rising Star by Northern California Super Lawyers.

Deshan Li
Executive Vice President, Senior Partner, Patent Attorney, Unitalen Attorneys at Law

Dr. Li joined a large patent and trademark law firm in 1996. As a patent attorney, attorney at law and director of the Electrical Department of that firm, Dr. Li has been very active in patent procurement and patent enforcement and accumulated extensive practical experience. He has successfully dealt with quite a number of difficult patent prosecution and litigation cases. Dr. Li’s practice focuses on the technical fields of image processing, telecommunication, computer science and automation etc. He also counsels clients on patent validity, patentability and infringement issues. In 2007, he joined Unitalen and is responsible for the management of foreign patent business.

He has been actively engaged in patent theory and practice research and published many articles in influential IP magazines, such as “Intellectual Property”. He is the co-author of “Chinese Patent Course”. In addition, he publishes the translation work, “Business Patent Strategy”. He also speaks frequently about the Chinese patent law and practice in international conferences and seminars.

Dr. Li has been invited as a patent law expert by SIPO to join the amendment of the Patent Law and its Implementing Regulations of China. A research group instructed by Dr. Li has conducted extensive study on “Patent Law Treaty” and got high praise from SIPO.
Sudesh Sivarasu

Associate Professor of Biomedical Engineering, University of Cape Town

Dr. Sudesh Sivarasu obtained his undergraduate degree in Electronics and Instrumentation Engineering from Madras University, followed by a Masters and Ph.D in Biomedical Engineering from VIT University, India. He is an Associate Professor of Biomedical Engineering from the University of Cape Town, where he heads the Medical Devices lab. Dr. Sudesh Sivarasu also holds an adjunct appointment as an international lecturer at the Northwestern University, Chicago for their Global Health Programme. In addition, Dr. Sivarasu head the activities of Biomedical Engineering Society of South Africa and an active member of the IFMBE-Working group for African Activities (WGAA).

Dr. Sivarasu conceptualized the ‘Frugal Biodesign’ methodology of medical device innovation and has implemented this in several developing countries. He is part of 19 medical device patent families and is lead inventor of over 43 patent applications and 7 granted patents. Sivarasu also holds over 75 peer reviewed publications. He has won over 14 national/international MedTech awards across 4 continents. Dr. Sivarasu has successfully produced 4 Ph.D graduates and over 23 Masters graduates in the field of biomedical engineering. His technologies were instrumentation in the formation of 2 active medical device start-ups companies in South Africa.

Zeqi Zhou

Dynamiker Biotechnology (Tianjin) Co., Ltd.

Prof. Zeqi Zhou has obtained the Ph.D. of Molecular and Cell Biology from Ohio University and accomplished postdoctoral research respectively at Tufts University School of Medicine and Harvard Medical School in USA. He has served as the Lecturer at Harvard Medical School, Senior Scientist of Bayer Corporation, Chief Scientist of Wyeth Pharmaceuticals and full-time Vice President of Tianjin International Joint Academy of Biotechnology and Medicine (TJAB). During his service at TJAB, he was honored as the “Leading Talent of Entrepreneurship in Beijing-Tianjin-Hebei Biomedicine Industrialization Demonstration Area” in 2008, was named winner of “Haihe River Friendship Award of Tianjin City” in 2012, and honored with the title of “Tianjin Good Man (with Professional Dedication)” on July 2013. He has obtained more than 10 patents, developed more than 20 products, published 40 plus scientific articles and delivered more than 30 speeches as well as reports.
Deon Bezuidenhout

Head of Biomaterials Research, Associate Professor, University of Cape Town

Deon Bezuidenhout holds a B.Sc. in Chemistry and Applied Mathematics, and M.Sc. (Cum Laude) and Ph.D. degrees in Polymer Science from Stellenbosch University, South Africa. As Associate Professor in the Christiaan Barnard Division of Cardiothoracic Surgery at the University of Cape Town (UCT) and Head of Biomaterials Sciences at the Cardiovascular Research Unit (CRU), he has more than 20 years research experience in the design, synthesis, modification, and processing of synthetic and bioprosthetic materials for use in cardiovascular devices, with specialization in the development of biomaterial scaffolds and biomimetic matrices for tissue engineering and regenerative medicine approaches to vascular grafts, heart valves, myocardial infarction therapy and allied applications. He has established masters and doctoral degrees in Biomaterials at UCT and teaches biomaterials science and medical device development to undergraduate and postgraduate students in Engineering, Medicine, Chemistry and other disciplines. He has published more than 60 papers and 10 book chapters in the field, and holds more than 30 international patents on cardiovascular devices and technologies. He is also co-founder and technical director of Strait Access Technologies, a university startup company developing affordable heart valve devices and related therapies for low and middle income countries (LMICs).

Derek Mathers

Director, Strategic Accounts, ASI Life Sciences

Derek is the Director of Strategic Accounts for ASI Life Sciences, a company focused on building a complete workflow for 3D biofabrication. By forging relationships with healthcare technology companies, research institutions, and regulatory bodies, he and his team are working to democratize access the world’s first six-axis 3D tissue printing platform.

Derek recently served as Entrepreneur-in-Residence to both GE Ventures and GE Healthcare, focused on evaluating strategic corporate investments in emerging private companies in the 3D printing for healthcare space. He also worked for Worrell, a medical device design firm where he led the global sales consulting team.

Derek graduated from the University of Minnesota’s Carlson School of Management with a degree focused on Marketing and Entrepreneurial Finance. Months after graduating, Derek went back to the Minnesota part-time to teach the university’s first 3D printing class as an Adjunct, where he did so for four semesters.
Thiagarajan Keddin Alwar  
**Associate Professor, Sri Ramachandra Medical College**  
Dr. K. Thyagalarajan Alwar (KAT), is a medical doctor with interest in Physical Medicine and Rehabilitation. Dr. KAT is from Sri Ramachandra Institute of Higher Education and Research, Chennai, India. He is presently setting involved in setting up a full sport and rehab pitch in his institute which consists of 20 VICON T-series cameras along with 2 High-Speed BONITA Video camera, 14 AMTI force plates spread over cricket batting and bowling areas and 16 channel MYON Wireless EMG system. He is also presently designing a professional MSc-Biomechanics programme. His research center is accredited as a testing center by International Cricket Council. Dr. KAT, would be talking on the advent of the usage of modern medical infrastructures its impact on sports performance enhancement and also increased clinical efficacy in Physical Medicine and Rehabilitation.

Andrea Giovanni Cutti  
**University di Bologna**  
Andrea Giovanni Cutti received the Master in Electronic Engineering, the PhD in Biomedical Engineering and the bachelor in Prosthetics and Orthotics from the University of Bologna, Italy. He is currently Chair of the International Shoulder Group (technical group of the International Society of Biomechanics) and member of the ISO 168 Committee WG1 and WG3. He received the Thranhardt Award from the American Prosthetic and Orthotic Association (AOPA) in 2017. He is currently Applied Research Manager of Centro Protesi INAIL, Italy.

Jazmin Aguado-Sierra  
**PhD, Barcelona Supercomputing Center (BSC)**  
Jazmin Aguado-Sierra is a Researcher at the Department of Computer Applications in Science and Engineering at the Barcelona Supercomputing Center. She leads the cardiovascular research lines in the center, being directly involved in the biomedical aspects of the BSC’s spin-off company ELEM Biotech. She received her PhD in Bioengineering from Imperial College London in 2008. She held a Post-Doctoral Position at the Cardiac Mechanics Research Group of the Bioengineering Department of the University of California, San Diego from 2008 to 2011. Following a period at the Universitat Pompeu Fabra in Barcelona, she was a Visiting Academic at the University of Sheffield before starting her current position at the Barcelona Supercomputing Center in March 2012. Her main area of research is the mathematical modelling of the cardiac and vascular system.

David Capes  
**VP of R&D for Greater Asia, BD**
Eric (Zhixiong) Liu
Senior Director, R&D for Greater Asia, BD

Chengli Song
Executive Director, Shanghai Institute for Minimally Invasive Therapy, University of Shanghai for Science and Technology

In 2008, he was appointed as the distinguished professor of Shanghai Oriental Scholar, and now he is the executive deputy director of the research center of minimally invasive medical device engineering of the ministry of education of University of Shanghai For Science and Technology. The main research direction is minimally invasive medical devices, and currently the research focuses on minimally invasive surgical instruments, surgical robots and endoscopes. Among the graduate students under his guidance, three have won the graduate innovation fund project of University of Shanghai For Science and Technology. He has published more than 80 papers in international first-class scientific journals and conferences and participated in the preparation of an English monograph. He also launched the minimally invasive medical technology summer school and has successfully held five. Taught by Dr. Alfred Cuschieri, founder of laparoscopic surgery, he has researched in the field of minimally invasive surgical medical devices for over ten years, won the technical progress award and nomination award of European society of endoscopic surgery twice, and developed patented products for many international famous companies as the main research and development person, including Storz in Germany, Covidien in the United States and NiTi medical technology in Israel. After returning to China, he has undertaken provincial and municipal research projects, such as Natural Science Foundation of China, Shanghai Science and Technology Committee Pujiang talent project, Shanghai Science and Technology Committee scientific and technological breakthrough project, and Shanghai Science and Technology Committee industry-university-research medical project. He also is responsible for many enterprises horizontal issues and solved technical problems for enterprises.

Cyndi Zhai
General Manager, Shanghai HiMed Incubator
Boshi Zhang

D.M.D. Orthodontic Resident c/o 2019, University of California, Los Angeles

Boshi Jeff Zhang is a third-year Orthodontic resident at UCLA. He specializes in clinical orthodontic research relating to skeletal expansion and airway. He was born in Harbin, China and lived in the Chicago suburbs from the age of 7. He completed his undergraduate studies at Duke University where he obtained a Bachelor of Science in Biology with Minors in Psychology and Chemistry with Magna Cum Laude honors. He subsequently received his Doctor of Dental Medicine degree at the University of Pennsylvania where he graduated #1 in his class. He is fluent in English and Mandarin.

Emmanuel Dhiravia Sargunam

Professor at the Sri Ramachandra Institute of Higher Education and Research, (SRIHER) Chennai, India

Dr. Emmanuel Dhiravia Sargunam is a maxillofacial surgeon, he works as associate professor at the Sri Ramachandra Institute of Higher Education and Research, (SRIHER) Chennai, India. His interests are in indigenization of technology. Any technology that is new comes with a high cost. Developing countries have a huge population, which can benefit from this technology but cannot afford its cost. Dr. Emmanuel indigenously devised a measuring platform for precise measurement in orthognathic surgery for $200 while the cost of the equipment was $1000 and available only in the US. He has used simple Thermoformed splints for management of fractures in children1. Modified a load cell from a personal weighing scale for a study on bite force, as an alternative to a $5000 equipment6. Modified existing plates to be used in specific critical areas by removing a part of it but still maintaining its strength2. He had used C-Arm for inter-operative use to assess fracture reduction in Zygomatic Fractures and has got favorable results3,4.

Haofei Wang

Executive President of BJHPA, President of BIOVAS, Cofounder of RAYS Venture Capital

He is an entrepreneur with extensive experience in the medical industry. He started his career as orthopedic surgeon at Beijing Jishuitan hospital, then successively served as north China market development manager of Cordis JJMC. executive President of BJHPA, president of BIOVAS, cofounder of RAYS Venture Capital.
Boston Scientific

Founded in 1979 and headquartered in Natick, Massachusetts, Boston Scientific is the world's leading medical technology company. In 1997, Boston Scientific entered China. At present, it has set up branches and R&D centers in Beijing, Shanghai and Guangzhou. The company's headquarters in China is located in Shanghai. Core business areas of Boston Scientific in China are cardiac intervention, cardiac rhythm management and electrophysiology, structural heart disease, endoscopic intervention, respiratory, peripheral and tumor intervention, and urinary and women's health. Since entering China, Boston Scientific has always maintained a high growth of performance in China. China will be one of the markets of strategic significance for the future development of Boston Scientific. In recent years, the company has continuously increased its investment in many fields in the Chinese market, such as infrastructure, product research and development, professional education, talent training, etc.

Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere.

Every day, our more than 130,000 employees across the world are blending heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Ansys China

Founded in 1970, ANSYS is headquartered south of Pittsburgh, Pennsylvania, U.S.A. Employs nearly 3,000 professionals, many of whom are expert M.S. and Ph.D.-level engineers in finite element analysis, computational fluid dynamics, electronics, semiconductors, embedded software and design optimization. Our exceptional staff is passionate about pushing the limits of world-class simulation technology, so our customers can turn their design concepts into successful, innovative products faster and at lower cost. As a measure of our success in attaining these goals, ANSYS has been recognized as one of the world’s most innovative companies by prestigious publications such as Bloomberg Businessweek and FORTUNE magazines.

If you've ever seen a rocket launch, flown on an airplane, driven a car, used a computer, touched a mobile device, crossed a bridge or put on wearable technology, chances are you've used a product where ANSYS software played a critical role in its creation. ANSYS is the global leader in engineering simulation. Through our strategy of Pervasive Engineering Simulation, we help the world’s most innovative companies deliver radically better products to their customers. By offering the best and broadest portfolio of engineering simulation software, we help them solve the most complex design challenges and create products limited only by imagination.
Schwegman Lundberg & Woessner

Schwegman is a law firm focused on creating value for our clients by applying our expertise in intellectual property law to obtain, evaluate, and develop patents. We are privileged to serve an international roster of clients that includes:

- Multinational corporations;
- Middle-market businesses;
- Startups;
- Universities; and
- Individuals.

Our clients benefit from the high-quality, value-added strategic counseling and client service that are our hallmark.

LifeTech Scientific Corporation

LifeTech Scientific Corporation (Stock Code: 1302.HK) is the leading supplier of minimally invasive interventional medical devices to treat cardiovascular diseases. The company specializes in R&D, manufacture and sales, and its high-quality, innovative, proprietary products are extensively marketed in more than 90 countries by over 300 distributors. At present, the company is the world second largest supplier (and the largest among BRIC countries) of occluders to treat congenital heart diseases and the second largest supplier of aortic repair device in Asia Pacific.

Lifetech Scientific (Shenzhen) Co., Ltd., the subsidiary of Lifetech, was established in 1999, and other subsidiaries and sales offices were subsequently setup in Hong Kong, India, Netherland, France, Russia, America, Greece, Beijing, Shanghai, Guangzhou and etc. In November 2011, the company was successfully listed on the Hong Kong Stock Exchange with the market cap over 10 billion HKD.

As a result of its pursuit for quality and innovation, the quality system of LifeTech Scientific Corporation was accredited by the DEKRA in EU (ISO13485: 2003), and passed inspection of Good Manufacturing Practice for Chinese Medical Devices. The company was rated as a National High-Tech Enterprise in 2008, and has obtained scientific research qualifications such as National Post-Doctoral Research Center, National and Local Joint Engineering Laboratory, etc. The company has also undertaken more than 50 government research projects, including the National Key Technology Research and Development Program of China under the “Tenth Five-Year Plan, the National Basic Research Program (973 Program) and the National High Technology Research and Development Program of China (863 Program). At the end of 2017, 6 products of the company have been approved as innovative medical devices by China Food and Drug Administration (CFDA).

Going forward, LifeTech Scientific Corporation is committed to enriching its product portfolio, improving product quality and enhancing medical services, to provide safe and innovative medical devices for doctors and patients globally and consistently contribute to the development of the industry.
Medtronic

Medtronic, Inc., founded in 1949 and headquartered in Minneapolis, Minnesota, is the world’s leading medical technology company. The company is committed to providing lifelong treatment for patients with chronic diseases. Medtronic’s main products cover many fields, such as arrhythmia, heart failure, vascular diseases, cardiac valve replacement, external cardiac support, minimally invasive cardiac surgery, malignant and non-malignant pain, movement disorders, diabetes, gastrointestinal diseases, urinary system diseases, spinal diseases, neurological diseases and surgical treatment of facial features, etc. Medtronic is working with more business partners to improve global healthcare through innovative models. Medtronic has the ability to meet the medical needs of more patients around the world after acquiring Covidien and incorporating it into the minimally invasive treatment business group. Acting on medical needs we are committed to improving human life through medical technology and solutions. By working with Covidien, we are able to further enhance our ability to bring meaningful innovation to hospitals, health systems, and health workers to help them deliver quality care to patients and their families around the world.

3M

Founded in 1902, 3M is headquartered in St. Paul, Minnesota, USA. As one of the world’s leading diversified technology innovation enterprises, 3M’s products and technologies have been deeply integrated into people's lives. Over the past 100 years, 3M has developed nearly 70,000 products, from household products to medical products, from transportation, construction to commerce, education and electronic and communication fields. 3M China Co., Ltd. was incorporated in China in November 1984 and is affiliated to 3M company. It is the first wholly foreign-owned enterprise in China established outside Shenzhen Special Economic Zone. Up to now, 3M has established 11 production bases, 27 offices, 4 technical centers and 2 R&D centers in China, with more than 8,200 employees. As one of the first foreign-funded enterprises entering into China, 3M China has always kept a close grasp of the pulse of China's economic development over the past 30 years, adhered to the localization development strategy of "rooted in China, serving China", and actively supported the construction and development of China's economy with diversified technologies and solutions. From infrastructure construction to the rise of manufacturing industry, from made in China to created in China, from export-driven to promoting domestic demand, 3M closely linked its development strategy with the development pace of China and helped the rapid development of Chinese market. This has made 3M one of the most successful companies to localize in China.

Abbott

Abbott is a global, diversified healthcare company with more than 100 years of history, about 73,000 employees worldwide, and operations in more than 150 countries and regions. Abbott continues to bring new solutions in nutrition, diagnostics, medical devices and pharmaceuticals to help people at all stages of life lead better lives around the world. Abbott has been operating in China for nearly 30 years, supplying a wide range of nutrition, pharmaceuticals and medical products to Chinese consumers. In addition to its China headquarters in Shanghai, Abbott now has 10 offices, three factories and two research and development centers, employing more than 4,000 people. Abbott has continued to invest in the Chinese market since 2010, developing, manufacturing and distributing products in China covering nutrition, pharmaceuticals, medical devices and diagnostic products to ensure that our products and services meet the full range of needs from disease prevention to diagnosis and from treatment to recovery. Abbott attaches great importance to the R&D capability in China. We not only set up the R&D center in Shanghai, but also set up the Shanghai Children’s Medical Center with our partners. Abbott China’s R&D capabilities have been greatly enhanced through local clinical trials and operations. In terms of medical innovation, we cooperate with other research and development centers around the world to cope with global medical problems. At Abbott, our belief in the limitless potential of life has led us to continue to deliver quality products and services from newborns to adults, from nutrition and diagnostics to health care and medical treatment. Our passion and care make science an inexhaustible source of healthy life. We are committed to stimulating everyone’s best potential and pursuing a healthier and better life.
BD

BD is a medical technology company that develops, produces and sells medical equipment, medical systems and reagents. BD is not only committed to improving human health worldwide, but also is dedicated to improving drug delivery, improving the quality and speed of the diagnosis of infectious diseases and cancer, and promoting the development and production of new drugs and vaccines. BD company has strong research and development ability to fight against various intractable diseases in the world. The company was founded in 1897 in New York, headquartered in franklin lake, New Jersey, the United States, with business throughout the world. The business of the company can be divided into three categories: BD medical treatment, BD diagnosis and BD biological science. Production sales include medical supplies, laboratory instruments, antibodies, reagents, diagnosis and other products. The company serves medical institutions, life sciences research institutes, clinical laboratories, industrial units and the general public.
CONFERENT SERVICE

I. Conference Address:

Beijing International Conference Center (BICC)
No.8, Bei Chen Dong Lu, Chaoyang, Beijing, China
The Beijing International Convention Center is located in the flourishing Yayuncun area along Beijing’s North Fourth Ring Road, where the central axis of the city meets the Fourth Ring Road, and right next to national stadiums like the Bird's Nest and the Water Cube. It’s a 20km trip east to the airport, a 9km journey south to Tian’anmen Square, a 10km excursion west to the Summer Palace, and an 80km sojourn north to the Badaling section of the Great Wall. And with the Olympic Village only a stone’s throw away, there is no better location in the city from which to base your business trip.
Distance from Beijing Capital International Airport: 40 minutes by car.

II. Hotel

Beijing North Star Continental Grand Hotel
No.8, Bei Chen Dong Lu, Chaoyang, Beijing, China
Located in the heart of Asian Olympic business circle, Beijing Continental Grand Hotel is landmark building of North Fourth Ring Road An Hui Qiao. The hotel is next to Beijing International Convention Center, within walk distance of Bird’s Nest, Water Cube and Olympic Park, and is very near to many science and technology parks (such as Zhongguancun, Wangjing, Shangdi). Situated in middle of Beijing north fourth road, the hotel is surrounded by large-scale shopping malls with services of eating, drinking and fun (such as Beichen Shi Dai Ming Men Store, Beichen Shi Dai Life Square, Beichen Shopping Center).
Website: http://www.bcghotel.com/
Distance from Beijing Capital International Airport: 40 minutes by car.
Distance from Beijing International Convention Center: 5 minutes on foot.

Beijing Parkview Wuzhou Hotel
Beijing Parkview Wuzhou Hotel is in the Asian Games Village area, adjacent to the Beijing International Conference, the National Convention Center, and the Olympic Park (Bird's Nest). The hotel is conveniently located only 25 minutes driving from the Beijing Capital International Airport. It is a short walk from 3 subway stations. It is convenient for business districts and places of interest such as downtown, Xiushui Street, Tiananmen Square, Forbidden City, and Summer Palace.
Website: http://www.v-continent.com/

III. Transportation (Transportation in Beijing is too busy. The following traffic hours are only for reference.)

Beijing Capital International Airport to BICC
Taxi: 27 kilometers, about 40 minutes by taxi. The fee is about 70 RMB.
Metro: Take Airport Line to Sanyuanqiao Station, transfer to Line 10, arrive at Beitucheng Station, then transfer to Line 8 and get off from Olympic Sports Center Station (B2 Exit), walk 1.2 kilometers to Beijing International Conference Center, about 80 minutes;

Beijing South Railway Station to BICC
Taxi: About 28 kilometers, 37 minutes. The fee is about 72 RMB.
Metro: Take Line 14 to Puhuangyu Station, transfer to Line 5, arrive at Huixinxijie Beikou Station, then get off (CExit), walk 2.4 kilometers to Beijing International Conference Center, about 70 minutes;
Take Line 4 to Pinganli Station, transfer to Line 6, arrive at Nanluoguxiang Station, then transfer to Line 8 and get off from Olympic Sports Center Station (B2 Exit), walk 1.2 kilometers to Beijing International Conference Center, about 71 minutes;

Take Line 4 to Xizhimen Station, transfer to Line 2, arrive at Guloudajie Station, then transfer to Line 8 and get off from Olympic Sports Center Station (B2 Exit), walk 1.2 kilometers to Beijing International Conference Center, about 72 minutes;

IV. Conference WeChat Subscription

V. Conference WeChat Group

CONFERENCE CONTACT

Ms Liu
Phone: +86-010-53360896
Email: AriaLiu@ASEBeijing.com

Ms Yan
Phone: +86-010-53360896
Email: LyndaYan@ASEBeijing.com

Ms Xiu
Phone: +86-010-53360896
Email: Yuexiu@ASEBeijing.com

Jenny Holden, Conference Administrator
Email: rampi002@umn.edu

Trisha Huntosh, Conference Coordinator
Email: johnsont@umn.edu